A Phase I Study of Inotuzumab Ozogamicin (CMC-544) in Combination With Temsirolimus (CCI-779) in Patients With Relapsed or Refractory CD22-positive B-cell Non Hodgkin's Lymphomas.
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Temsirolimus (Primary)
- Indications B cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- 06 Jun 2016 Status changed from recruiting to completed.
- 17 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 17 Sep 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.